LESSONS AND NEW PERSPECTIVES: IS CONVALESCENT PLASMA THERAPY EFFECTIVE ON COVID-19 PATIENTS?

Authors

  • HERNITA TAURUSTYA Department of Pharmacology and Therapeutic, Faculty of Medicine and Health Sciences University of Bengkulu, Bengkulu, Indonesia
  • SRI YUNITA Department of Physiology, Faculty of Medicine and Health Sciences University of Bengkulu, Bengkulu, Indonesia https://orcid.org/0000-0002-5980-7525
  • YSRAFIL YSRAFIL Department of Pharmacy, Health Polytechnic of Gorotalo, Gorontalo, Indonesia
  • NUKE PRATIWI Undergraduate of Medical Sciences, Faculty of Medicine and Health Sciences University of Bengkulu, Bengkulu, Indonesia
  • ANINDITA RAHMATIAH Undergraduate of Medical Sciences, Faculty of Medicine and Health Sciences University of Bengkulu, Bengkulu, Indonesia

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42452

Keywords:

Convalescent plasma, COVID-19, Effectivity, neutralizing antibody, SARS-CoV2, Therapy

Abstract

Objective: Recently, convalescent plasma (CP) therapy has shown promising evidence in the treatment of several serious contagious diseases, including SARS-CoV, Influenza and Ebola. We conducted a systematic review to extract data about using CP treatment for COVID-19 patients and its effectivity.

Methods: The retrieval of studies was conducted according to Cochrane Collaboration and from electronic databases including PubMed, Medline, and others (medRxiv and BioRxiv). Searching of available evidence concerning CP treatment of COVID-19 patients was conducted in journal articles published between December 2019 and October 2020. The articles were further screened based on inclusion and exclusion criteria to identify the high quality studies for analysis.

Results: A total of 18 CP studies were included in this review. We found variance regarding the effectiveness of CP in the reduction of mortality rate, length of stay, and increased discharging rate. Several findings show CP therapy is effective in increasing viral negativity, neutralizing antibodies to recipients, does not cause harmful adverse reactions and in some cases can improve clinical symptoms. This therapy is presently considered effective for generating good clinical outcomes when given early in the course of the disease.

Conclusion: The effectiveness of CP in terms of mortality, length of stay, and increased discharging patients is still debatable. However, CP therapy is effective to increase the negativity of SARS-CoV-2 test, neutralizing antibody titer and is safe so it can be considered for COVID-19 patients. CP should not be given in the initial disease course but is recommended for the early disease course.

Downloads

Download data is not yet available.

References

Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020;14(4):407-12.

Ysrafil Y, Astuti I, Mus R, Gama NI, Rahmaisyah D, Nur’amalia R. A Summary of Coronavirus Disease 2019: What We Should Know ? Pharm Sci 2020;26(Covid-19):S24-S35.

Viscusi WK. Pricing the global health risks of the COVID-19 pandemic. J Risk Uncertain 2020:1-28.

Pak A, Adegboye OA, Adekunle AI, Rahman KM, McBryde ES, Eisen DP. Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness. Front Public Health 2020;8:241.

Rizkita LD, Martien R, Ysrafil Y, Astuti I. Chitosan Nanoparticles Mediated Delivery of miR-106b-5b to Breast Cancer Cell Lines MCF-7 and T47D. Int J App Pharm 2021;13(1):129-34.

Ysrafil, Mus R, Gama NI, Rahmaisyah D, Nur'amalia R. Emerging Mutation in SARS-CoV-2 Spike: Widening Distribution Over Time in Different Geographic Areas. Biomedical journal 2021.

WHO. Coronavirus (COVID-19). https://who.sprinklr.com/: WHO; 2020.

Singh M, Nagpal M, Singh V, Sharma A, Dhingra GA, Maman P, et al. COVID-19: Epidemiology, pathogenicity and global updates. Int J App Pharm 2020;12(5):16-28.

Horton R. Offline: COVID-19 is not a pandemic. Lancet 2020;396(10255):874.

Yadav UN, Rayamajhee B, Mistry SK, Parsekar SS, Mishra SK. A Syndemic Perspective on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low- and Middle-Income Countries. Front Public Health 2020;8:508.

Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 2020;28(3):357-66.

Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24(1):44-6.

Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis 2020;98:334-46.

Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis 2015;41:3-5.

Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, Uyeki TM, et al. Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. Clin Infect Dis 2015;61(6):969-73.

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020.

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bmj 2020;371:m3939.

AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. medRxiv 2020:1-17.

Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R, Torres F, et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv 2020:1-15.

Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, et al. Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial. medRxiv 2020:1-23.

Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, et al. Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial. medRxiv 2020:1-25.

Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv 2020:1-16.

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. Jama 2020;324(5):460-70.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117(17):9490-6.

Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci 2020:102867.

Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of Convalescent Plasma is associated with Clinical Improvement in Critically Ill Patients With Covid-19: A Comment. Rev Invest Clin 2020;72(3):159-64.

Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol 2020;190(11):2290-303.

Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. Infect Dis Ther 2020.

Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci 2020:102875.

Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci 2020:102955.

Omrani AS, Zaqout A, Baiou A, Daghfal J, Elkum N, Alattar RA, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. J Med Virol 2020.

Wu Y, Hong K, Ruan L, Yang X, Zhang J, Xu J, et al. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study. Virol Sin 2020:1-8.

Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis 2020;222(1):38-43.

Ng KT, Oong XY, Lim SH, Chook JB, Takebe Y, Chan YF, et al. Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections. Clin Infect Dis 2018;67(2):261-8.

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9(1):382-5.

Murphy K, Travers P, Walport M, Janeway C. Janeway's Immunobiology. 8th ed. New York: Garland Science; 2012.

French MA, Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Respirology 2020;25(7):680-2.

Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion 2020;60(8):1765-72.

Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020;19(7):102554.

Published

02-11-2021

How to Cite

TAURUSTYA, H., YUNITA, S., YSRAFIL, Y., PRATIWI, N., & RAHMATIAH, A. (2021). LESSONS AND NEW PERSPECTIVES: IS CONVALESCENT PLASMA THERAPY EFFECTIVE ON COVID-19 PATIENTS?. International Journal of Applied Pharmaceutics, 14(1). https://doi.org/10.22159/ijap.2022v14i1.42452

Issue

Section

Review Article(s)

Most read articles by the same author(s)